Appraisal of immune response in lymphoproliferative syndromes: A systematic review

Critical Reviews in Oncology/Hematology

Volumn 70, Issue 2, 2009, Pages 103-113

  Álvaro, Tomás ^a   Lejeune, Marylène ^a   Escrivá, Patricia ^a   Pons, Lluís E ^a   Bosch, Ramón ^a   Jaén, Joaquín ^a   López, Carlos ^a   Salvadó, Maria Teresa ^a   de Sanjosé, Silvia ^b,c  

^a HOSPITAL VERGE DE LA CINTA   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Immune markers; Immunohistochemistry; Lymphoproliferative disorders; Prognosis; Survival analysis

Indexed keywords

BIOLOGICAL MARKER;

ACCESSORY CELL; B CELL LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

HODGKIN DISEASE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 63249136260     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.09.013     Document Type: Review

References (59)

1. Sanchez-Beato M., Sanchez-Aguilera A., and Piris M.A. Cell cycle deregulation in B-cell lymphomas. Blood 101 4 (2003) 1220-1235
2. Berglund M., Thunberg U., Amini R.M., et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 18 8 (2005) 1113-1120
3. Garcia J.F., Camacho F.I., Morente M., et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101 2 (2003) 681-689
4. Bai M., Skyrlas A., Agnantis N.J., et al. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. Anticancer Res 25 1A (2005) 347-362
5. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 18 10 (2005) 1377-1384
6. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970) 1-27
7. Gatti R.A., and Good R.A. Aging, immunity, and malignancy. Geriatrics 25 9 (1970) 158-168
8. Burns E.A., and Leventhal E.A. Aging, immunity, and cancer. Cancer Control 7 6 (2000) 513-522
9. Newell G.R., Spitz M.R., and Sider J.G. Cancer and age. Semin Oncol 16 1 (1989) 3-9
10. Tomita N., Kanamori H., Fujimaki K., Fujisawa S., and Ishigatsubo Y. Epstein-Barr virus-associated extranodal NK/T-cell lymphoma following mosquito bites in an elderly patient without prior hypersensitivity. Leuk Lymphoma 45 10 (2004) 2153-2155
11. Sorensen H.T., Mellemkjaer L., Nielsen G.L., Baron J.A., Olsen J.H., and Karagas M.R. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 96 9 (2004) 709-711
12. Ichim C.V. Revisiting immunosurveillance and immunostimulation: implications for cancer immunotherapy. J Transl Med 3 1 (2005) 1-13
13. Ikeda H., Old L.J., and Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13 2 (2002) 95-109
14. Peipp M., and Valerius T. Bispecific antibodies targeting cancer cells. Biochem Soc Trans 30 4 (2002) 507-511
15. Smyth M.J., Hayakawa Y., Takeda K., and Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2 11 (2002) 850-861
16. Adam J.K., Odhav B., and Bhoola K.D. Immune responses in cancer. Pharmacol Ther 99 1 (2003) 113-132
17. Gonthier M., Llobera R., Arnaud J., and Rubin B. Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo. J Immunol 173 11 (2004) 7062-7069
18. Aldinucci D., Olivo K., Lorenzon D., et al. The role of interleukin-3 in classical Hodgkin's disease. Leuk Lymphoma 46 3 (2005) 303-311
19. Atkinson E.A., and Bleackley R.C. Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 15 3-4 (1995) 359-384
20. Berke G. The CTL's kiss of death. Cell 81 1 (1995) 9-12
21. de Visser K.E., and Kast W.M. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13 8 (1999) 1188-1199
22. Skinnider B.F., and Mak T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 99 12 (2002) 4283-4297
23. Poupot M., Pont F., and Fournie J.J. Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human gamma delta T cells to anaplastic large cell lymphoma. J Immunol 174 3 (2005) 1717-1722
24. Staveley-O'Carroll K., Sotomayor E., Montgomery J., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95 3 (1998) 1178-1183
25. Flynn S., and Stockinger B. Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. Blood 101 11 (2003) 4472-4478
26. Yang S.C., Hillinger S., Riedl K., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10 8 (2004) 2891-2901
27. Elahi M.M., McMillan D.C., McArdle C.S., et al. The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma. Med Sci Monit 11 2 (2005) CR75-CR78
28. Alvaro T., Lejeune M., Salvado M.T., et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 24 34 (2006) 5350-5357
29. Alvaro T., Lejeune M., Camacho F.I., et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 91 12 (2006) 1605-1612
30. Lee A.M., Clear A.J., Calaminici M., et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24 31 (2006) 5052-5059
31. Glas A.M., Knoops L., Delahaye L., et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25 4 (2007) 390-398
32. Farinha P., Masoudi H., Skinnider B.F., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106 6 (2005) 2169-2174
33. Carreras J., Lopez-Guillermo A., Fox B.C., et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108 9 (2006) 2957-2964
34. Ansell S.M., Stenson M., Habermann T.M., Jelinek D.F., and Witzig T.E. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 19 3 (2001) 720-726
35. Xu Y., Kroft S.H., McKenna R.W., and Aquino D.B. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol 112 4 (2001) 945-949
36. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 5 (2007) 1167-1174
37. Rimsza L.M., Roberts R.A., Miller T.P., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103 11 (2004) 4251-4258
38. Muris J.J., Meijer C.J., Cillessen S.A., et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 18 3 (2004) 589-596
39. Monti S., Savage K.J., Kutok J.L., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105 5 (2005) 1851-1861
40. Riemersma S.A., Oudejans J.J., Vonk M.J., et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol 206 3 (2005) 328-336
41. Bladergroen B.A., Meijer C.J., ten Berge R.L., et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood 99 1 (2002) 232-237
42. Mori T., Takada R., Watanabe R., Okamoto S., and Ikeda Y. T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother 50 10 (2001) 566-568
43. Pedersen L.M., Jurgensen G.W., and Johnsen H.E. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br J Haematol 128 6 (2005) 813-819
44. Jones E.A., Pringle J.H., Angel C.A., and Rees R.C. Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leuk Lymphoma 43 6 (2002) 1313-1321
45. Novak A.J., Grote D.M., Stenson M., et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104 8 (2004) 2247-2253
46. ten Berge R.L., Meijer C.J., Dukers D.F., et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99 12 (2002) 4540-4546
47. ten Berge R.L., Oudejans J.J., Dukers D.F., Meijer J.W., Ossenkoppele G.J., and Meijer C.J. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia 15 3 (2001) 458-464
48. Janik J.E., Morris J.C., Pittaluga S., et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 104 10 (2004) 3355-3357
49. Vermeer M.H., van Doorn R., Dukers D., Bekkenk M.W., Meijer C.J., and Willemze R. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 19 23 (2001) 4322-4329
50. Rook A.H., Zaki M.H., Wysocka M., et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann NY Acad Sci 941 (2001) 177-184
51. Tiemessen M.M., Mitchell T.J., Hendry L., Whittaker S.J., Taams L.S., and John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 126 10 (2006) 2217-2223
52. Alvaro-Naranjo T., Lejeune M., Salvadó-Usach M., et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma. A quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 46 11 (2005) 1581-1591
53. Alvaro T., Lejeune M., Salvado M.T., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11 4 (2005) 1467-1473
54. Bosch R., Lejeune M., Salvadó M., Jaén J., Pons L., and Álvaro T. Decreased number of granzyme-B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol 84 10 (2005) 661-666
55. Bai M., Tsanou E., Agnantis N.J., et al. Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas. Histol Histopathol 18 2 (2003) 449-457
56. Azuma T., Takahashi T., Kunisato A., Kitamura T., and Hirai H. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 63 15 (2003) 4516-4520
57. Alvaro T., Lejeune M., Garcia J.F., et al. Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res 14 3 (2008) 685-691
58. Focosi D., and Petrini M. CD57 expression on lymphoma microenvironment as a new prognostic marker related to immune dysfunction. J Clin Oncol 25 10 (2007) 1289-1291 [author reply 1291-2]
59. Canioni D., Salles G., Mounier N., et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26 3 (2008) 440-446